InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

- Current share price for LTP : $0.500

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$91 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2024 8:40AM $1.305 $0.500 fallen by 61.69%
$91 SPONTAN Final Study Results 14 Oct 2024 9:04AM $1.930 $0.500 fallen by 74.09%
$91 Appendix 4G and Corporate Governance Statement 30 Aug 2024 9:29AM $1.770 $0.500 fallen by 71.75%
$91 FY24 Results Announcement 30 Aug 2024 9:29AM $1.770 $0.500 fallen by 71.75%
$91 Appendix 4E and Annual Financial Report 30 Aug 2024 9:27AM $1.770 $0.500 fallen by 71.75%
$91 SPONTAN Prescribed to First Patient by Authorised Prescriber 16 Aug 2024 9:05AM $1.375 $0.500 fallen by 63.64%
$91 LTP Secures Global CoDevelopment Agreement with Aptar Pharma 13 Aug 2024 9:17AM $0.965 $0.500 fallen by 48.19%
$91 Mens Health Expert Prescribes SPONTAN 8 Aug 2024 9:16AM $0.790 $0.500 fallen by 36.71%
$91 SPONTAN prescribed to First Patient Under TGA 5 Aug 2024 9:02AM $0.730 $0.500 fallen by 31.51%
$91 Cleansing Notice 31 Jul 2024 11:42AM $0.770 $0.500 fallen by 35.06%
$91 Application for quotation of securities - LTP 31 Jul 2024 11:36AM $0.770 $0.500 fallen by 35.06%
$91 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2024 9:35AM $0.880 $0.500 fallen by 43.18%
$91 Investor Webinar 24 Jul 2024 10:33AM $0.800 $0.500 fallen by 37.50%
$91 Investor Presentation 24 Jul 2024 9:09AM $0.900 $0.500 fallen by 44.44%
$91 Proposed issue of securities - LTP 24 Jul 2024 9:09AM $0.900 $0.500 fallen by 44.44%
$91 LTR Pharma completes A$10.5 million placement 24 Jul 2024 9:09AM $0.900 $0.500 fallen by 44.44%
$91 Trading Halt 22 Jul 2024 8:46AM $0.900 $0.500 fallen by 44.44%
$91 Reinstatement to quotation 7 Jun 2024 11:39AM $0.640 $0.500 fallen by 21.88%
$91 SPONTAN achieves positive clinical study results 7 Jun 2024 11:39AM $0.640 $0.500 fallen by 21.88%
$91 Suspension from Quotation 6 Jun 2024 10:42AM $0.640 $0.500 fallen by 21.88%
$91 Trading Halt 4 Jun 2024 9:11AM $0.640 $0.500 fallen by 21.88%
$91 Response to ASX Price Query 22 May 2024 3:44PM $0.495 $0.500 risen by 1.01%
$91 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2024 9:38AM $0.255 $0.500 risen by 96.08%
$91 Notification regarding unquoted securities - LTP 18 Apr 2024 4:59PM $0.280 $0.500 risen by 78.57%
$91 Final Patients dosed in SPONTAN pivotal study 25 Mar 2024 9:05AM $0.305 $0.500 risen by 63.93%

101 - 125 of 152 results

Page 5 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.